Core Insights - Windtree Therapeutics, Inc. has announced the issuance of a patent in Japan for its oncology aPKCi inhibitor, a novel drug candidate aimed at treating hedgehog pathway-dependent cancers, with the patent expiring in 2040 [1][3] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, with a portfolio that includes istaroxime for acute heart failure and preclinical aPKCi inhibitors for oncology applications [4] Product Development - The aPKCi inhibitor platform is a high-potency, specific drug candidate with applications in treating various cancers, including basal cell carcinoma and small cell lung cancer, and includes both topical and oral formulations developed in collaboration with Cancer Research UK [2][3] - The company is also pursuing additional intellectual property to expand its patent portfolio globally [3]
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline